Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMKLR1 | Q99788 | 7/20 | 0.38 |
| ▸ | USP14 | P54578 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 5/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | KHK | P50053 | 4/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6182817 | 0.99 | ESR1 (0.39) | CMKLR1USP14PDE4APDE4BPDE4C | |
| SCHEMBL3602939 | 0.84 | ESR1 (0.41) | CMKLR1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3167730 | 0.78 | PDE4A (0.41) | PDE4APDE4BPDE4CPDE4DESR1 | |
| SCHEMBL683162 | 0.78 | ESR1 (0.40) | PDE4APDE4BPDE4CPDE4DESR1 | |
| SCHEMBL7727228 | 0.78 | GRM4 (0.39) | USP14KHKDRD2DRD3 | |
| SCHEMBL6796557 | 0.77 | PTGDR2 (0.47) | PDE4APDE4BPDE4CPDE4DESR1 | |
| SCHEMBL6185088 | 0.77 | ESR1 (0.42) | PDE4APDE4BPDE4CPDE4DESR1 | |
| SCHEMBL27428244 | 0.77 | ESR1 (0.40) | CMKLR1PDE4APDE4BPDE4CPDE4D | |
| Bromide SCHEMBL7526402 | 0.76 | ESR1 (0.41) | PDE4APDE4BPDE4CPDE4DESR1 | |
| SCHEMBL27552667 | 0.76 | ESR1 (0.41) | PDE4APDE4BPDE4CPDE4DESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1422849-A | indazole derivatives | PFIZER (US) | 2003-06-11 | — | — | CN | claimed |
| EP-0912521-B1 | SUBSTITUTED INDAZOLE DERIVATIVES AND THEIR USE AS INHIBITORS PHOSPHODIESTERASE (PDE) TYPE IV AND THE PRODUCTION OF TUMOR NECROSIS FACTOR (TNF) | PFIZER (US) | 2005-04-06 | — | — | EP | disclosed |
| US-6716978-B2 | FOR THERAPY AND PROHYLAXIS OF INFLAMMATORY DISEASES INCLUDING JOINT INFLAMMATION, CROHN'S DISEASE, AND INFLAMMATORY BOWEL DISEASE; RESPIRATORY DISEASES SUCH AS CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) INCLUDING ASTHMA, CHRONIC BRONCHITIS | PFIZER INC | 2004-04-06 | — | — | US | disclosed |
| US-20030158189-A1 | Therapeutically active compounds based on indazole bioisostere replacement of catechol in PDE4 inhibitors | MARFAT ANTHONY (US) | 2003-08-21 | — | — | US | disclosed |
| CN-1112359-C | Substituted indazole derivatives and their use as Phosphodiesterase (PDE) type IV and inhibitors of the production of Tumor Necrosis Factor (TNF) | PFIZER (US) | 2003-06-25 | — | — | CN | disclosed |
| CN-1422849-A | indazole derivatives | PFIZER (US) | 2003-06-11 | — | — | CN | disclosed |
| US-6391872-B1 | SENSITIVE TO ADRENERGIC ANTAGONIST | PFIZER INC | 2002-05-21 | — | — | US | disclosed |
| US-20020058687-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS BASED ON INDAZOLE BIOISOSTERE REPLACEMENT OF CATECHOL IN PDE4 INHIBITORS | MARFAT ANTHONY (US) | 2002-05-16 | — | — | US | disclosed |
| US-6211222-B1 | Substituted indazole derivatives and related compounds | PFIZER INC | 2001-04-03 | — | — | US | disclosed |
| CN-1284948-A | Indazole bioisostere replacement of catechol in therapeutically active compounds | PFIZER PROD INC (US) | 2001-02-21 | — | — | CN | disclosed |
| CN-1281441-A | Therapeutically active compounds based on indazole bioisostere replacement of catechol in PDE4 inhibitors | PFIZER PROD INC (US) | 2001-01-24 | — | — | CN | disclosed |
| US-6127398-A | Substituted indazole derivatives and related compounds | PFIZER INC (US) | 2000-10-03 | — | — | US | disclosed |
| CN-1217714-A | Substituted indazole derivatives and their use as Phosphodiesterase (PDE) type IV and inhibitors of the production of Tumor Necrosis Factor (TNF) | PFIZER (US) | 1999-05-26 | — | — | CN | disclosed |
| EP-0912521-A1 | SUBSTITUTED INDAZOLE DERIVATIVES AND THEIR USE AS INHIBITORS PHOSPHODIESTERASE (PDE) TYPE IV AND THE PRODUCTION OF TUMOR NECROSIS FACTOR (TNF) | PFIZER INC. (US) | 1999-05-06 | — | — | EP | disclosed |
| WO-1997042174-A1 | SUBSTITUTED INDAZOLE DERIVATIVES AND THEIR USE AS INHIBITORS PHOSPHODIESTERASE (PDE) TYPE IV AND THE PRODUCTION OF TUMOR NECROSIS FACTOR (TNF) | PFIZER INC. (US) | 1997-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158189-A1 | Therapeutically active compounds based on indazole bioisostere replacement of catechol in PDE4 inhibitors | PDE4B, PDE3B, PDE4A | CMKLR1 1235/4885USP14 1861/4885PDE4A 3/4885 |
| US-20020058687-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS BASED ON INDAZOLE BIOISOSTERE REPLACEMENT OF CATECHOL IN PDE4 INHIBITORS | PDE3B, ALPI, PDE4B | CMKLR1 1481/4885USP14 2637/4885PDE4A 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.